Precise risk stratification of prostate cancer
Technology
PRECAST – a robust validated multi-gene expression (mRNA) based test differentiating aggressive from indolent prostate cancer. Precisely quantifies risk of disease progression over 5 and 10 years.
Market
The global prostate cancer diagnostics market was valued at USD 4.5 billion in 2023 and is projected to grow at a CAGR of 10% from 2024 to 2032.
Uniqueness
- Clinically actionable – distinguishes aggressive from indolent disease, using standard formalin-fixed paraffin-embedded (FFPE) tissue biopsies, reducing both under- and overtreatment.
- Healthcare-ready – compatible with public healthcare systems and standard clinical care pathways.
- Proven performance – validated in 414 FFPE samples with known clinical outcomes.
Status
- Patent filing in progress.
- Seeking commercial partners and licensees.
